AstraZeneca: lung cancer drug approved in China

(CercleFinance.com) - The Group announces that its Enhertu treatment has been approved in China as the first HER2-directed therapy for patients with HER2-mutant metastatic non-small cell lung cancer.


The conditional approval from the National Medical Products Administration (NMPA) is based on positive results from the DESTINY-Lung02 and DESTINY-Lung05 phase II trials. Full approval for this indication will depend on the clinical benefits of a confirmatory trial.

Every year in China, over one million people are diagnosed with lung cancer, accounting for over 40% of lung cancer patients worldwide - the majority of whom are diagnosed at an advanced stage of the disease.

A principal investigator said that although there have been many advances in the treatment of non-small cell lung cancer in China in recent years, patients with HER2-mutant disease have had few treatment options, and none directed at this specific type of lung cancer. Enhertu's approval provides an important new targeted therapy for patients with this aggressive form of the disease.


Copyright (c) 2024 CercleFinance.com. All rights reserved.